FDA ad­comm backs ac­cel­er­at­ed ap­proval of Sarep­ta's Duchenne gene ther­a­py in close vote

An FDA ad­vi­so­ry com­mit­tee vot­ed 8-6 on Fri­day that the ben­e­fits of Sarep­ta Ther­a­peu­tics’ gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy out­weigh its risks, lend­ing their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER